Teva Pharma (TEVA) PT Raised to $37 at BofA Securities

BofA Securities analyst Jason Gerberry raised the price target on Teva Pharma (NYSE: TEVA) to $37.00 (from $36.00) while maintaining a Buy rating.

The analyst comments "We modestly increase our TEVA PO to $37 (from $36) after TEVA delivered a solid 4Q update. Overall, we were encouraged by the strength of the brand business and FY26 guidance, the latter making us more comfortable on execution of cost efficiency program (mitigates g-Revlimid 1x LOE). When we look beyond the '26E roll-off of gRevlimid, we see a guide that indicates mid-SD revenue growth on adjusted basis and TEVA's brand portfolio positions the company for sustainable growth and operating leverage. We reiterate Buy on re-rate to growth multiple."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)